| Clarissa Morrison-heffern, PHARMD | |
|
2160 W Drake Rd, Fort Collins, CO 80526-1486 | |
| (970) 484-2843 | |
| Not Available |
| Full Name | Clarissa Morrison-heffern |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 2160 W Drake Rd, Fort Collins, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083914063 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 18363 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Clarissa Morrison-heffern, PHARMD 2160 W Drake Rd, Fort Collins, CO 80526-1486 Ph: () - | Clarissa Morrison-heffern, PHARMD 2160 W Drake Rd, Fort Collins, CO 80526-1486 Ph: (970) 484-2843 |
News Archive
Nutranomics, Inc. is pleased to provide this update regarding the GenEpic prostate cancer human clinical study that is currently underway. Nutranomics has previously announced a non-binding Letter of Intent with Genesar Nutraceuticals, LLC with the intent of completing a licencing agreement to market and distribute GenEpic globally.
Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.
Peplin Limited today announced positive results from its Australian phase IIa clinical trial of its proprietary drug PEP005 Topical in superficial forms of basal cell carcinoma (sBCC) the most common form of skin cancer.
For years, doctors have warned patients to finish their antibiotic prescriptions or risk a renewed infection by a "superbug" that can mount a more powerful defense against the same drug. But a new study by Boston University biomedical engineers indicates that treating bacteria with levels of antibiotics insufficient to kill them produces germs that are cross-resistant to a wide range of antibiotics.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.
› Verified 8 days ago
Anuj Basnet, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2190 W Drake Rd, Fort Collins, CO 80526 Phone: 970-484-5841 | |
Jason Deboodt, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2160 W Drake Rd, Fort Collins, CO 80526 Phone: 970-484-2843 Fax: 970-490-2774 | |
Dr. Hafiz Tayebali, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 105 W Troutman Pkwy, Fort Collins, CO 80525 Phone: 970-223-0840 | |
Debra Lyons, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 600 S Drive, Fort Collins, CO 80523 Phone: 970-491-1402 Fax: 970-491-4874 | |
Dr. Lindsay Nicole Curry, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 460 S College Ave, Fort Collins, CO 80524 Phone: 970-484-9534 Fax: 970-484-8367 | |
Dr. Steven Schoeber, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1426 E Harmony Rd, Fort Collins, CO 80525 Phone: 970-223-2556 | |
Dr. Jennifer Petrie, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2025 Bighorn Rd, Fort Collins, CO 80525 Phone: 970-449-0082 |